Huadong Medicine (000963.SZ): The clinical trial of HDM1005 injection, a long-acting agonist targeting both peptide human GLP-1 receptor and GIP receptor, has been approved.

Huadong Medicine (000963.SZ) announced on March 3, 2025 that its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (referred to as "Zhongmei Huadong"), has received the Drug Clinical Trial Approval Notice (Notice No.: 2025LP00511 and 2025LP00512) issued by the National Medical Products Administration (NMPA) for the clinical trial application of HDM1005 injection. HDM1005 injection is a first-class chemical new drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. with global intellectual property rights. It is a dual-target long-acting agonist of GLP-1 (glucagon-like peptide-1) receptor and GIP (glucose-dependent insulinotropic peptide) receptor. Preclinical studies have shown that HDM1005 can activate GLP-1 and GIP receptors, promote cyclic adenosine monophosphate (cAMP) production, increase insulin secretion, suppress appetite, delay gastric emptying, improve metabolic function, and subsequently improve plasma volume, reduce oxidative stress and systemic inflammation, improve cardiovascular adaptability, and have effects on lowering blood sugar, weight loss, improving metabolic associated fatty liver disease (MAFLD) and heart failure with preserved ejection fraction (HFpEF). Existing data also indicate that HDM1005 has good pharmacokinetic properties and safety. HDM1005 injection is a dual-target long-acting agonist of GLP-1 and GIP receptors, and GLP-1 products have effects on weight loss, blood sugar reduction, and cardiovascular benefits. This clinical approval for HDM1005 injection marks another important milestone in the product's development process, which will further enhance the company's core competitiveness in the field of endocrinology therapy.